{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:05Z","timestamp":1792114145391,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Featured Clinical Discipline Project of Shanghai Pudong District","award":["PWYts2021-06"],"award-info":[{"award-number":["PWYts2021-06"]}]},{"name":"Key Specialty Construction Project of Shanghai Pudong New Area Health Commission","award":["PWZzk2022-17"],"award-info":[{"award-number":["PWZzk2022-17"]}]},{"name":"the Fund from Shanghai East Hospital","award":["DFRC2018014"],"award-info":[{"award-number":["DFRC2018014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Traditional nanodrug delivery systems have some limitations, such as eliciting immune responses and inaccuracy in targeting tumor microenvironments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Targeted drugs (Sorafenib, Sora) nanometers (hollow mesoporous silicon, HMSN) were designed, and then coated with platelet membranes to form aPD-1-PLTM-HMSNs@Sora to enhance the precision of drug delivery systems to the tumor microenvironment, so that more effective immunotherapy was achieved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>These biomimetic nanoparticles were validated to have the same abilities as platelet membranes (PLTM), including evading the immune system. The successful coating of HMSNs@Sora with PLTM was corroborated by transmission electron microscopy (TEM), western blot and confocal laser microscopy. The affinity of aPD-1-PLTM-HMSNs@Sora to tumor cells was stronger than that of HMSNs@Sora. After drug-loaded particles were intravenously injected into hepatocellular carcinoma model mice, they were demonstrated to not only directly activate toxic T cells, but also increase the triggering release of Sora. The combination of targeted therapy and immunotherapy was found to be of gratifying antineoplastic function on inhibiting primary tumor growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The aPD-1-PLTM-HMSNs@Sora nanocarriers that co-delivery of aPD-1 and Sorafenib integrates unique biomimetic properties and excellent targeting performance, and provides a neoteric idea for drug delivery of personalized therapy for primary hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-12006-1","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T12:02:19Z","timestamp":1708948939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets"],"prefix":"10.1186","volume":"24","author":[{"given":"Xuanbo","family":"Da","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukai","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beining","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"issue":"10","key":"12006_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3760\/cma.j.issn.0253-3766.2018.10.004","volume":"23","author":"KR Wei","year":"2018","unstructured":"Wei KR, Zheng RS, Liang ZH, et al. [Incidence and mortality of laryngeal cancer in China, 2014]. Zhonghua Zhong Liu Za Zhi. Oct. 2018;23(10):736\u201343. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2018.10.004.","journal-title":"Oct"},{"issue":"3","key":"12006_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12072-018-9921-7","volume":"13","author":"N Nishida","year":"2019","unstructured":"Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int May. 2019;13(3):248\u201352. https:\/\/doi.org\/10.1007\/s12072-018-9921-7.","journal-title":"Hepatol Int May"},{"issue":"1","key":"12006_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"11","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther Aug. 2020;11(1):146. https:\/\/doi.org\/10.1038\/s41392-020-00264-x.","journal-title":"Signal Transduct Target Ther Aug"},{"key":"12006_CR4","doi-asserted-by":"publisher","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. May 2018;15(5):325\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29.","DOI":"10.1038\/nrclinonc.2018.29"},{"issue":"1","key":"12006_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"30","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer Mar. 2019;30(1):60. https:\/\/doi.org\/10.1186\/s12943-019-0974-6.","journal-title":"Mol Cancer Mar"},{"issue":"6","key":"12006_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med Jun. 2014;20(6):607\u201315. https:\/\/doi.org\/10.1038\/nm.3541.","journal-title":"Nat Med Jun"},{"key":"12006_CR7","doi-asserted-by":"publisher","first-page":"1016817","DOI":"10.3389\/fimmu.2022.1016817","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li C, Lu Y, Liu C, Yang W. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol. 2022;13:1016817. https:\/\/doi.org\/10.3389\/fimmu.2022.1016817.","journal-title":"Front Immunol"},{"issue":"7","key":"12006_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1166\/jbn.2018.2546","volume":"1","author":"G Lin","year":"2018","unstructured":"Lin G, Chen S, Mi P. Nanoparticles targeting and remodeling Tumor Microenvironment for Cancer Theranostics. J Biomed Nanotechnol Jul. 2018;1(7):1189\u2013207. https:\/\/doi.org\/10.1166\/jbn.2018.2546.","journal-title":"J Biomed Nanotechnol Jul"},{"issue":"9","key":"12006_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1166\/jbn.2020.2976","volume":"1","author":"L Zhao","year":"2020","unstructured":"Zhao L, Liu H, Xing Y, et al. Tumor Microenvironment-Specific Functional nanomaterials for Biomedical Applications. J Biomed Nanotechnol Sep. 2020;1(9):1325\u201358. https:\/\/doi.org\/10.1166\/jbn.2020.2976.","journal-title":"J Biomed Nanotechnol Sep"},{"issue":"7","key":"12006_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","volume":"4","author":"F Balkwill","year":"2004","unstructured":"Balkwill F. Cancer and the chemokine network. Nat Rev Cancer Jul. 2004;4(7):540\u201350. https:\/\/doi.org\/10.1038\/nrc1388.","journal-title":"Nat Rev Cancer Jul"},{"issue":"32","key":"12006_CR11","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.1016\/j.biomaterials.2011.07.032","volume":"32","author":"H Wang","year":"2011","unstructured":"Wang H, Zhao Y, Wu Y, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials Nov. 2011;32(32):8281\u201390. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.07.032.","journal-title":"Biomaterials Nov"},{"issue":"2","key":"12006_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.22074\/cellj.2016.4308","volume":"18","author":"MM Ochi","year":"2016","unstructured":"Ochi MM, Amoabediny G, Rezayat SM, Akbarzadeh A, Ebrahimi B. In Vitro Co-delivery evaluation of Novel Pegylated Nano-Liposomal Herbal drugs of Silibinin and Glycyrrhizic Acid (Nano-Phytosome) to Hepatocellular Carcinoma cells. Cell J Jul-Sep. 2016;18(2):135\u201348. https:\/\/doi.org\/10.22074\/cellj.2016.4308.","journal-title":"Cell J Jul-Sep"},{"issue":"7","key":"12006_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1166\/jbn.2021.3116","volume":"1","author":"ZQ Zhao","year":"2021","unstructured":"Zhao ZQ, Song W, Yan XQ, et al. Autophagy modulation and synergistic therapy to Combat Multidrug resistance breast Cancer using hybrid cell membrane nanoparticles. J Biomed Nanotechnol Jul. 2021;1(7):1404\u201316. https:\/\/doi.org\/10.1166\/jbn.2021.3116.","journal-title":"J Biomed Nanotechnol Jul"},{"key":"12006_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2016.02.036","volume":"28","author":"J Li","year":"2016","unstructured":"Li J, Sharkey CC, Wun B, Liesveld JL, King MR. Genetic engineering of platelets to neutralize circulating tumor cells. J Control Release Apr. 2016;28:228:38\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2016.02.036.","journal-title":"J Control Release Apr"},{"issue":"44","key":"12006_CR15","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1002\/adma.201503323","volume":"25","author":"Q Hu","year":"2015","unstructured":"Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Anticancer Platelet-Mimicking Nanovehicles. Adv Mater Nov. 2015;25(44):7043\u201350. https:\/\/doi.org\/10.1002\/adma.201503323.","journal-title":"Adv Mater Nov"},{"issue":"4","key":"12006_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/anie.201709457","volume":"22","author":"L Rao","year":"2018","unstructured":"Rao L, Bu LL, Ma L, et al. Platelet-facilitated Photothermal Therapy of Head and Neck squamous cell carcinoma. Angew Chem Int Ed Engl Jan. 2018;22(4):986\u201391. https:\/\/doi.org\/10.1002\/anie.201709457.","journal-title":"Angew Chem Int Ed Engl Jan"},{"issue":"1","key":"12006_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/ar400091e","volume":"21","author":"Y Chen","year":"2014","unstructured":"Chen Y, Chen HR, Shi JL. Construction of homogenous\/heterogeneous hollow mesoporous silica nanostructures by silica-etching chemistry: principles, synthesis, and applications. Acc Chem Res Jan. 2014;21(1):125\u201337. https:\/\/doi.org\/10.1021\/ar400091e.","journal-title":"Acc Chem Res Jan"},{"issue":"23","key":"12006_CR18","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood.2019004119","volume":"10","author":"S Lazar","year":"2021","unstructured":"Lazar S, Goldfinger LE. Platelets and extracellular vesicles and their cross talk with cancer. Blood Jun. 2021;10(23):3192\u2013200. https:\/\/doi.org\/10.1182\/blood.2019004119.","journal-title":"Blood Jun"},{"key":"12006_CR19","doi-asserted-by":"publisher","first-page":"793006","DOI":"10.3389\/fonc.2021.793006","volume":"11","author":"M Chen","year":"2021","unstructured":"Chen M, Wang P, Jiang D, Bao Z, Quan H. Platelet membranes coated Gold Nanocages for Tumor targeted Drug Delivery and Amplificated Low-Dose Radiotherapy. Front Oncol. 2021;11:793006. https:\/\/doi.org\/10.3389\/fonc.2021.793006.","journal-title":"Front Oncol"},{"key":"12006_CR20","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.2147\/IJN.S333279","volume":"16","author":"L Wu","year":"2021","unstructured":"Wu L, Li Q, Deng J, et al. Platelet-tumor cell hybrid membrane-camouflaged nanoparticles for enhancing Therapy Efficacy in Glioma. Int J Nanomed. 2021;16:8433\u201346. https:\/\/doi.org\/10.2147\/IJN.S333279.","journal-title":"Int J Nanomed"},{"issue":"1","key":"12006_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11706-021-0539-7","volume":"15","author":"YF Zhang","year":"2021","unstructured":"Zhang YF, Peng XY, Jing XB, et al. Synthesis of pH-responsive triazine skeleton nano-polymer composite containing AIE group for drug delivery. Front Mater Sci Mar. 2021;15(1):113\u201323. https:\/\/doi.org\/10.1007\/s11706-021-0539-7.","journal-title":"Front Mater Sci Mar"},{"issue":"43","key":"12006_CR22","doi-asserted-by":"publisher","first-page":"9581","DOI":"10.1002\/adma.201602173","volume":"28","author":"H Sun","year":"2016","unstructured":"Sun H, Su J, Meng Q, et al. Cancer-Cell-Biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater Nov. 2016;28(43):9581\u20138. https:\/\/doi.org\/10.1002\/adma.201602173.","journal-title":"Adv Mater Nov"},{"issue":"2","key":"12006_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nnano.2012.237","volume":"8","author":"A Salvati","year":"2013","unstructured":"Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol Feb. 2013;8(2):137\u201343. https:\/\/doi.org\/10.1038\/nnano.2012.237.","journal-title":"Nat Nanotechnol Feb"},{"issue":"3","key":"12006_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11706-021-0568-2","volume":"15","author":"QN Xu","year":"2021","unstructured":"Xu QN, Li CH, Chen YQ, Zhang YL, Lu B. Metal-organic framework-based intelligent drug delivery systems for cancer theranostic: a review. Front Mater Sci Sep. 2021;15(3):374\u201390. https:\/\/doi.org\/10.1007\/s11706-021-0568-2.","journal-title":"Front Mater Sci Sep"},{"key":"12006_CR25","doi-asserted-by":"publisher","unstructured":"Wang S, Duan Y, Zhang Q, et al. Drug targeting via platelet membrane-coated nanoparticles. Small Struct Oct. 2020;1(1). https:\/\/doi.org\/10.1002\/sstr.202000018.","DOI":"10.1002\/sstr.202000018"},{"issue":"22","key":"12006_CR26","doi-asserted-by":"publisher","first-page":"e2001704","DOI":"10.1002\/smll.202001704","volume":"16","author":"Q Jiang","year":"2020","unstructured":"Jiang Q, Wang K, Zhang X, et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced Cancer Immunotherapy. Small Jun. 2020;16(22):e2001704. https:\/\/doi.org\/10.1002\/smll.202001704.","journal-title":"Small Jun"},{"issue":"9","key":"12006_CR27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"Q Hu","year":"2021","unstructured":"Hu Q, Li H, Archibong E, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat Biomed Eng Sep. 2021;5(9):1038\u201347. https:\/\/doi.org\/10.1038\/s41551-021-00712-1.","journal-title":"Nat Biomed Eng Sep"},{"issue":"43","key":"12006_CR28","doi-asserted-by":"publisher","first-page":"9573","DOI":"10.1002\/adma.201603463","volume":"28","author":"Q Hu","year":"2016","unstructured":"Hu Q, Qian C, Sun W, et al. Engineered nanoplatelets for enhanced treatment of multiple myeloma and Thrombus. Adv Mater Nov. 2016;28(43):9573\u201380. https:\/\/doi.org\/10.1002\/adma.201603463.","journal-title":"Adv Mater Nov"},{"key":"12006_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.biomaterials.2016.10.003","volume":"111","author":"X Wei","year":"2016","unstructured":"Wei X, Gao J, Fang RH, et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials Dec. 2016;111:116\u201323. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.10.003.","journal-title":"Biomaterials Dec"},{"issue":"6","key":"12006_CR30","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1073\/pnas.061615598","volume":"13","author":"L Borsig","year":"2001","unstructured":"Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S Mar. 2001;13(6):3352\u20137. https:\/\/doi.org\/10.1073\/pnas.061615598.","journal-title":"Proc Natl Acad Sci U S Mar"},{"issue":"3","key":"12006_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1055\/s-0034-1370767","volume":"40","author":"HA Goubran","year":"2014","unstructured":"Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost Apr. 2014;40(3):296\u2013305. https:\/\/doi.org\/10.1055\/s-0034-1370767.","journal-title":"Semin Thromb Hemost Apr"},{"issue":"30","key":"12006_CR32","doi-asserted-by":"publisher","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","volume":"29","author":"M Labelle","year":"2014","unstructured":"Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S Jul. 2014;29(30):E3053\u201361. https:\/\/doi.org\/10.1073\/pnas.1411082111.","journal-title":"Proc Natl Acad Sci U S Jul"},{"issue":"8","key":"12006_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol Aug. 2016;13(8):473\u201386. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58.","journal-title":"Nat Rev Clin Oncol Aug"},{"issue":"9","key":"12006_CR34","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest Sep. 2015;125(9):3384\u201391. https:\/\/doi.org\/10.1172\/JCI80011.","journal-title":"J Clin Invest Sep"},{"issue":"7571","key":"12006_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature15373","volume":"1","author":"CMJ Hu","year":"2015","unstructured":"Hu CMJ, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nat Oct. 2015;1(7571):118\u2013. https:\/\/doi.org\/10.1038\/nature15373.","journal-title":"Nat Oct"},{"key":"12006_CR36","first-page":"251","volume":"13","author":"QY Hu","year":"2016","unstructured":"Hu QY, Sun WJ, Qian CG, Wang C, Bomba H, Gu Z. Anticancer platelet-mimicking nanovehicles. Abstr Pap Am Chem S. Mar 2016;13:251.","journal-title":"Abstr Pap Am Chem S"},{"key":"12006_CR37","doi-asserted-by":"publisher","unstructured":"Hu QY, Sun WJ, Qian CG, Bomba HN, Xin HL, Gu Z. Relay Drug Delivery for Amplifying Targeting Signal and enhancing Anticancer Efficacy. Adv Mater Apr 4 2017;29(13)doi:ARTN 1605803. https:\/\/doi.org\/10.1002\/adma.201605803","DOI":"10.1002\/adma.201605803"},{"issue":"8","key":"12006_CR38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer Aug. 2008;8(8):592\u2013603. https:\/\/doi.org\/10.1038\/nrc2442.","journal-title":"Nat Rev Cancer Aug"},{"key":"12006_CR39","doi-asserted-by":"publisher","unstructured":"Jaszai J, Schmidt MHH. Trends and challenges in Tumor anti-angiogenic therapies. Cells Sep. 2019;18(9). https:\/\/doi.org\/10.3390\/cells8091102.","DOI":"10.3390\/cells8091102"},{"issue":"21","key":"12006_CR40","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1158\/1078-0432.CCR-09-3389","volume":"1","author":"KF Chen","year":"2010","unstructured":"Chen KF, Tai WT, Liu TH, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res Nov. 2010;1(21):5189\u201399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3389.","journal-title":"Clin Cancer Res Nov"},{"issue":"4","key":"12006_CR41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/hep.23836","volume":"52","author":"H Hikita","year":"2010","unstructured":"Hikita H, Takehara T, Shimizu S, et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatol Oct. 2010;52(4):1310\u201321. https:\/\/doi.org\/10.1002\/hep.23836.","journal-title":"Hepatol Oct"},{"issue":"4","key":"12006_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C. Immunomodulatory effects of current targeted therapies on Hepatocellular Carcinoma: implication for the future of Immunotherapy. Semin Liver Dis Nov. 2018;38(4):379\u201388. https:\/\/doi.org\/10.1055\/s-0038-1673621.","journal-title":"Semin Liver Dis Nov"},{"issue":"12","key":"12006_CR43","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci Dec. 2018;109(12):3993\u20134002. https:\/\/doi.org\/10.1111\/cas.13806.","journal-title":"Cancer Sci Dec"},{"issue":"6","key":"12006_CR44","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1590\/s0100-879x2001000600003","volume":"34","author":"A Varki","year":"2001","unstructured":"Varki A, Varki NM. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz J Med Biol Res Jun. 2001;34(6):711\u20137. https:\/\/doi.org\/10.1590\/s0100-879x2001000600003.","journal-title":"Braz J Med Biol Res Jun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12006-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T12:03:39Z","timestamp":1708949019000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12006-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12006"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12006-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Animal Welfare Committee of Stomatological Hospital of Tongji University approved all animal experimental protocols used in this study (NO.2020-DW-02). All mice were housed under standard laboratory conditions (12\u00a0h\/12\u00a0h light\/dark cycle and 22\u2009\u00b1\u20091\u2103) and accessible to food (ordinary solid food) and water freely. Furthermore, all methods are reported per the ARRIVE guidelines (\n                      \n                      ) for reporting animal experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}